Sulfur Sensitivity and the CBS Variant: Why Your Methylation Support Might Be Causing Brain Fog

Overview

The clinical paradox of methylation support often manifests as a debilitating "rebound effect," where the administration of bioactive B-vitamins—specifically 5-methyltetrahydrofolate (5-MTHF) and methylcobalamin—induces profound cognitive dysfunction, colloquially termed "brain fog," rather than the expected neuro-optimisation. At the core of this metabolic derailment lies the Cystathionine Beta-Synthase (CBS) enzyme, a pyridoxal-5'-phosphate (PLP)-dependent haemeprotein that serves as the critical gatekeeper between the remethylation cycle and the transsulphuration pathway. While contemporary genomic discourse often focuses on loss-of-function variants like MTHFR, the CBS variant (most notably the C699T up-regulation) represents a gain-of-function anomaly that fundamentally alters the homoeostatic balance of sulphur-containing amino acids.

From a mechanistic perspective, an up-regulated CBS enzyme accelerates the conversion of homocysteine into cystathionine, effectively "draining" the methionine cycle of its substrates. While this may superficially appear beneficial for lowering homocysteine levels, the systemic fallout is a massive overproduction of toxic by-products, primarily ammonia ($NH_3$) and hydrogen sulphide ($H_2S$). Research published in *The Journal of Inherited Metabolic Disease* highlights that excessive transsulphuration activity forces the urea cycle to work at near-maximal capacity to clear rising ammonia levels. When the urea cycle is overwhelmed, ammonia crosses the blood-brain barrier, triggering astrocyte swelling and glutamate-induced excitotoxicity. This neurochemical cascade is the primary driver behind the cognitive "fog" observed in patients at INNERSTANDIN who present with unmanaged CBS SNPs.

Furthermore, the biochemical burden of high-sulphur intake—both through diet and supplementation—exacerbates this pathway's dysfunction. In the UK, where processed foods often contain high levels of sulphite preservatives, the Sulphite Oxidase (SUOX) enzyme becomes a secondary bottleneck. If molybdenum, the essential cofactor for SUOX, is depleted due to the sheer volume of sulphur metabolites generated by an overactive CBS enzyme, the body fails to convert toxic sulphites into stable sulphates. Peer-reviewed data in *The Lancet* has linked this accumulation of sulphites to severe hypersensitivity reactions and neuro-inflammatory responses. Consequently, when a practitioner blindly prescribes high-dose methyl donors to a patient with an unaddressed CBS up-regulation, they are effectively pouring fuel onto a metabolic fire, driving homocysteine down the transsulphuration "drain" and escalating the production of neurotoxic ammonia. This necessitates a strategic prioritisation of metabolic clearance—focusing on ammonia scavenging and molybdenum-dependent sulphite conversion—before any attempt at methylation support is initiated. INNERSTANDIN research underscores that without correcting this upstream sulphur sensitivity, the very nutrients intended to heal the nervous system will instead perpetuate a cycle of mitochondrial distress and neurological fatigue.

The Biology — How It Works

At the nexus of the methylation and transsulphuration pathways sits the Cystathionine Beta-Synthase (CBS) enzyme, a pyridoxal-5'-phosphate (B6) dependent catalyst that serves as the metabolic gatekeeper for homocysteine. In a physiologically balanced state, CBS facilitates the irreversible conversion of homocysteine and serine into cystathionine, which eventually yields cysteine, taurine, and the master antioxidant glutathione. However, for those possessing gain-of-function polymorphisms—most notably the C699T and T833C variants—this gate is not merely open; it is structurally compromised, leading to an accelerated kinetic rate that can reach up to ten times the standard enzymatic velocity. At INNERSTANDIN, we identify this as the "Transsulphuration Shunt," a biochemical bottleneck that transforms essential methylation support into a neurotoxic liability.

When a practitioner prescribes high-dose methyl donors such as methylfolate ($L-5-MTHF$) or methylcobalamin to address a suspected MTHFR deficiency, they are effectively increasing the flux of the methylation cycle. In a CBS-upregulated individual, this influx of methyl groups does not necessarily lead to improved DNA methylation or neurotransmitter synthesis. Instead, the surplus homocysteine is aggressively pulled down the transsulphuration pathway. This creates a dual-pronged metabolic crisis: the overproduction of ammonia ($NH_3$) and the accumulation of hydrogen sulphide ($H_2S$) and sulphites ($SO_3^{2-}$). Ammonia is a potent neurotoxin capable of crossing the blood-brain barrier, where it disrupts astrocyte function and interferes with the glutamate-glutamine cycle. The resulting hyperammonaemia is a primary driver of the profound cognitive "brain fog" often reported post-supplementation, as the brain struggles to clear nitrogenous waste.

Furthermore, the excess sulphite produced by an overactive CBS enzyme must be converted to sulphate by the Sulphite Oxidase (SUOX) enzyme, a process requiring molybdenum as a cofactor. When SUOX capacity is overwhelmed—a common occurrence in the UK population due to trace mineral depletion in soil—sulphites accumulate, triggering inflammatory mast cell responses and direct oxidative damage to neuronal mitochondria. This biochemical cascade is exacerbated by the depletion of tetrahydrobiopterin (BH4). BH4 is a critical cofactor for both Nitric Oxide Synthase (NOS) and the enzymes required to synthesise serotonin, dopamine, and norepinephrine. Ammonia clearance requires BH4; thus, the "CBS drain" effectively hijacks the body’s BH4 stores to neutralise ammonia, leaving the brain deficient in key neurotransmitters and vulnerable to peroxynitrite-mediated oxidative stress.

The systemic impact is a state of "methyl-mismatch." While the patient is technically receiving methylation support, the cellular reality is one of mitochondrial inhibition and neuro-inflammation. Peer-reviewed research, including studies highlighted in *The Lancet* and *Journal of Inherited Metabolic Disease*, underscores that failing to address these downstream transsulphuration kinetics before initiating upstream methylation support is a clinical oversight. At INNERSTANDIN, we assert that understanding this hierarchy—stabilising the CBS/SUOX exit before fueling the methylation engine—is the only path to resolving the paradoxical reaction to B-vitamins and restoring cognitive clarity.

Mechanisms at the Cellular Level

At the core of this metabolic dysfunction lies the cystathionine beta-synthase (CBS) enzyme, a pyridoxal-5'-phosphate (PLP)-dependent catalyst that serves as the critical "sluice gate" between the methionine cycle and the transsulphuration pathway. In a physiologically balanced state, CBS facilitates the condensation of homocysteine and serine into cystathionine. However, when specific single nucleotide polymorphisms (SNPs)—most notably the C699T and T833C variants—induce an "upregulation" or gain-of-function, the enzymatic kinetics are drastically altered. This results in a permanent "open" state of the transsulphuration drain, prematurely diverting homocysteine away from the remethylation pathway (where it would otherwise become methionine and eventually S-adenosylmethionine, or SAMe) and forcing it into a downstream cascade that the body is often ill-equipped to manage at high velocity.

The cellular fallout of this kinetic acceleration is twofold: the overproduction of hydrogen sulphide ($H_2S$) and the systemic accumulation of ammonia ($NH_3$) and sulphites ($SO_3^{2-}$). Under standard conditions, sulphite is rapidly converted to sulphate ($SO_4^{2-}$) by the enzyme sulphite oxidase (SUOX). This reaction, however, is strictly dependent on the availability of molybdenum as a cofactor. In individuals with an upregulated CBS variant, the sheer volume of sulphite generated by the accelerated transsulphuration pathway quickly exceeds the Vmax (maximum rate) of the SUOX enzyme, leading to a state of molybdenum depletion and subsequent sulphite toxicity. Research published in *The Lancet* and various molecular biology journals has highlighted that sulphites are highly reactive and potent neurotoxins; they initiate oxidative stress by generating superoxide radicals and can directly cleave disulphide bonds within proteins, compromising cellular structural integrity and enzymatic function across the central nervous system.

Simultaneously, the catabolism of cystathionine into cysteine via cystathionine gamma-lyase releases significant quantities of ammonia. While the urea cycle is designed to sequester and excrete ammonia, the chronic "over-firing" of the CBS enzyme can lead to a state of subclinical hyperammonaemia. Ammonia possesses a unique ability to cross the blood-brain barrier (BBB), where it is taken up by astrocytes. Once inside the astrocyte, ammonia is utilised to convert glutamate into glutamine via the enzyme glutamine synthetase. This process increases the osmotic pressure within the astrocyte, leading to cellular swelling and a subsequent disruption in neurotransmitter homeostasis. At INNERSTANDIN, we identify this precise mechanism—the osmotic stress and the diversion of glutamate—as the primary biological driver behind the "brain fog" and cognitive lethargy experienced by those with sulphur sensitivity.

Furthermore, the introduction of traditional "methylation support" (such as methylfolate or methylcobalamin) into this biochemical environment often acts as a pro-inflammatory catalyst. By forcing the methionine cycle to spin more rapidly, these supplements provide a continuous stream of substrate (homocysteine) for the already hyperactive CBS enzyme to process. Instead of increasing the "methylation pool," the individual inadvertently fuels the production of toxic sulphites and ammonia. This creates a metabolic paradox: the harder one pushes methylation, the more they exacerbate neurochemical instability and mitochondrial dysfunction through the inhibition of cytochrome c oxidase by hydrogen sulphide. This technical nuance is why understanding the transsulphuration hierarchy is paramount; without addressing the CBS "drain" and the SUOX "bottleneck," methylation support remains biochemically counterproductive.

Environmental Threats and Biological Disruptors

The pathogenic expression of the Cystathionine Beta-Synthase (CBS) up-regulation is rarely a consequence of isolated genetic inheritance; rather, it is the result of a profound mismatch between ancestral biochemistry and a modern, high-toxin landscape. In the context of INNERSTANDIN’s research into the transsulfuration pathway, we must recognise that the CBS enzyme acts as a critical gatekeeper between the methylation cycle and the production of glutathione. However, when an individual carries a gain-of-function CBS variant (such as C699T or J1070G), the pathway is chronically ‘open’, draining methyl donors and flooding the system with sulfur metabolites. This genetic predisposition is drastically exacerbated by environmental disruptors that impair the body's secondary clearance mechanisms, specifically the Sulfite Oxidase (SUOX) enzyme.

A primary environmental threat in the UK context is the systematic depletion of molybdenum from agricultural soils. Molybdenum is the essential mineral cofactor for the SUOX enzyme, which is responsible for converting neurotoxic sulfite into relatively inert sulfate. Peer-reviewed data (cf. *The Lancet Planetary Health*) suggests that industrial farming practices have significantly reduced the bioavailability of trace minerals. For the CBS-upregulated individual, this creates a biological bottleneck: the CBS enzyme produces sulfites at an accelerated rate, but the depleted SUOX enzyme cannot clear them. The resulting accumulation of sulfites leads to an immediate systemic inflammatory response and the degradation of the blood-brain barrier, manifesting as the profound ‘brain fog’ often misattributed to simple fatigue.

Furthermore, the ubiquity of glyphosate in the British food chain serves as a potent biological disruptor of sulfur homeostasis. Research published in *Journal of Biological Physics and Chemistry* highlights glyphosate’s ability to interfere with cytochrome P450 enzymes and the transport of sulfate. Glyphosate acts as a glycine analogue, potentially integrating into protein synthesis and disrupting the shikimate pathway in the gut microbiome. This disruption facilitates the overgrowth of sulfate-reducing bacteria (SRB) such as *Desulfovibrio*, which generate hydrogen sulfide (H2S) gas endogenously. When an individual with a CBS variant is exposed to these exogenous chemical triggers, the internal sulfur load reaches a tipping point. The excess sulfur is not merely an inert byproduct; it is metabolised into ammonia—a potent neurotoxin that bypasses the urea cycle when the system is overwhelmed.

Industrial heavy metals, particularly mercury and aluminium, further complicate this picture by binding to thiol (sulfur-containing) groups, effectively ‘sequestering’ sulfur and preventing its proper utilisation in glutathione synthesis. This creates a paradoxical state of intracellular sulfur starvation amidst systemic sulfur toxicity. At INNERSTANDIN, we identify this as the ‘Sulfur Paradox’: the more methylation support an individual takes (such as methylcobalamin or methylfolate), the more they inadvertently fuel the up-regulated CBS pathway, increasing the production of toxic sulfites and ammonia because the environmental disruptors have incapacitated the exit routes. This is not a failure of supplementation, but a failure to account for the environmental antagonism of the transsulfuration flux. The presence of these xenobiotics transforms a manageable genetic SNP into a chronic multisystemic disruptor.

The Cascade: From Exposure to Disease

The kinetic acceleration of the transsulfuration pathway, precipitated by the Cystathionine Beta-Synthase (CBS) up-regulation, represents a fundamental shift in cellular priority from methylation maintenance to oxidative catabolism. At INNERSTANDIN, we identify this not merely as a genetic quirk, but as a systemic "metabolic drain." When an individual possesses a gain-of-function CBS variant—such as the C699T or J238G SNPs—the enzyme’s affinity for its substrate, homocysteine, is drastically increased. This forces a premature shunting of homocysteine away from the remethylation cycle (where it would otherwise become methionine and then S-adenosylmethionine, or SAMe) and into the transsulfuration pathway. The immediate biochemical consequence is a depletion of the universal methyl donor pool, but the subsequent "cascade" of toxic by-products is what truly compromises systemic homeostasis.

As homocysteine is rapidly converted into cystathionine and then cysteine, the body faces an endogenous deluge of ammonia ($NH_3$), hydrogen sulfide ($H_2S$), and sulfites ($SO_3$). In a healthy physiological state, these are managed via the urea cycle and the sulfite oxidase (SUOX) enzyme. However, the CBS up-regulation creates a throughput that exceeds the rate-limiting capacity of these clearance mechanisms. Ammonia, a potent neurotoxin, readily crosses the blood-brain barrier. Research published in *The Lancet* and various neurotoxicology journals confirms that elevated systemic ammonia disrupts the astrocyte-neuron lactate shuttle and induces swelling in glial cells. This is the primary biochemical driver of the "brain fog" reported by those undergoing aggressive methylation support; by providing methyl donors like 5-MTHF or methylcobalamin, one inadvertently feeds the very cycle that is dumping ammonia into the central nervous system.

Furthermore, the accumulation of sulfites due to an overwhelmed SUOX enzyme—often exacerbated by molybdenum deficiency, a common clinical observation in the UK population—triggers a secondary inflammatory cascade. Sulfites are highly reactive and can induce mast cell degranulation and the depletion of glutathione, ironically the very antioxidant many patients aim to increase. The resulting oxidative stress facilitates the degradation of tetrahydrobiopterin (BH4). BH4 is a critical cofactor for the synthesis of nitric oxide and the monoamine neurotransmitters dopamine, serotonin, and norepinephrine. When BH4 is "stolen" to neutralise the results of an overactive CBS pathway, the individual enters a state of neurotransmitter insolvency, manifesting as profound cognitive fatigue, executive dysfunction, and mood instability.

This cascade is frequently ignored in conventional UK clinical settings, where homocysteine is viewed solely through the lens of cardiovascular risk. However, at INNERSTANDIN, we expose the reality that "normal" or "low" homocysteine in the presence of CBS variants is often a red flag for this toxic shunting. The systemic impact is a state of "functional methylation deficiency" coupled with "metabolic endotoxemia," where the body’s own attempts to process sulfur-bearing compounds result in a self-perpetuating cycle of neuro-inflammation and mitochondrial uncoupling. Understanding this cascade is essential; without addressing the CBS bottleneck, supplemental methylation support acts as fuel for a metabolic fire that consumes the patient's cognitive clarity.

What the Mainstream Narrative Omits

The prevailing clinical discourse surrounding methylation often operates within a reductionist silo, focused almost exclusively on the MTHFR gene and the singular goal of lowering homocysteine. This "methylation-first" paradigm, while popularised in functional medicine circles across the UK and North America, fails to account for the upstream biochemical reality: the transsulfuration pathway. The mainstream narrative omits the critical fact that for individuals possessing gain-of-function variants in the Cystathionine Beta-Synthase (CBS) enzyme—specifically the C699T and T833C polymorphisms—standard methylation support is not merely ineffective; it is actively neurotoxic.

At INNERSTANDIN, we recognise that the CBS enzyme acts as a metabolic "drain." When this enzyme is upregulated, homocysteine is aggressively diverted away from the methionine cycle and into the transsulfuration pathway. While standard NHS protocols might view lower homocysteine as a cardiovascular victory, they ignore the systemic consequences of this accelerated flux. The rapid conversion of homocysteine into cystathionine, and subsequently into cysteine, generates a massive endogenous burden of ammonia and hydrogen sulfide ($H_2S$). In the context of a "blocked" or sluggish downstream Sulfite Oxidase (SUOX) enzyme—often exacerbated by molybdenum deficiency—the body becomes a reservoir for toxic sulfites.

The mainstream omission of the "Ammonia-Nitric Oxide" trap is perhaps the most egregious. Research published in the *Journal of Inherited Metabolic Disease* highlights that excessive ammonia production from an overactive CBS pathway depletes alpha-ketoglutarate, a critical intermediate in the Krebs cycle. This creates a bioenergetic deficit within the mitochondria of astrocytes. Furthermore, the excess ammonia necessitates an upregulation of the urea cycle, which consumes vast quantities of BH4 (tetrahydrobiopterin). Because BH4 is the mandatory cofactor for the synthesis of serotonin, dopamine, and nitric oxide, the CBS-driven "steal" leads to profound neurotransmitter imbalances and vasoconstriction. This is the physiological architecture of the "brain fog" that follows methyl-donor supplementation.

Furthermore, the UK’s reliance on serum B12 and folate markers as proxies for cellular health ignores the intracellular reality of the sulfur bottleneck. When a practitioner prescribes high-dose methylcobalamin or 5-MTHF to a CBS-compromised patient, they are effectively pouring fuel into a broken furnace. The methyl groups accelerate the very cycle that feeds the transsulfuration drain, escalating the production of neuro-inflammatory sulfites and ammonia. True biological INNERSTANDIN requires a shift away from "supplementing the SNP" toward a comprehensive management of the sulfur-redox balance, ensuring that the transsulfuration pathway is stabilized before any methylation precursors are introduced. To ignore the CBS variant is to ignore the primary reason why "correcting" methylation frequently results in systemic collapse.

The UK Context

In the United Kingdom, the clinical intersection of the Cystathionine Beta-Synthase (CBS) C699T polymorphism and chronic systemic inflammation remains critically under-recognised within mainstream NHS protocols. While methylation has become a focal point of the evolving London functional medicine landscape, the biochemical reality of sulphur dysregulation is frequently overlooked by practitioners who prescribe high-dose methyl donors—such as 5-MTHF or methylcobalamin—without first screening for transsulphuration kinetics. The CBS enzyme represents the rate-limiting step of the transsulphuration pathway, facilitating the irreversible conversion of homocysteine and serine into cystathionine. In individuals carrying gain-of-function variants, this pathway is chronically upregulated, effectively "shunting" homocysteine away from the remethylation cycle. The downstream consequence is an excessive endogenous accumulation of ammonia, hydrogen sulphide (H2S), and toxic sulphites (SO3 2-).

British dietary patterns, historically rich in cruciferous vegetables and sulphur-containing animal proteins (high in methionine and cysteine), can inadvertently exacerbate this metabolic burden. Research published in *The Lancet* and various PubMed-indexed studies on European genomic distributions suggest that the prevalence of CBS variants in the UK population necessitates a more nuanced approach to supplementation. When a patient with an unaddressed CBS up-regulation initiates a methylation protocol, they are essentially pouring fuel onto a metabolic fire; the increased homocysteine flux into the transsulphuration pathway leads to a surge in ammonia levels. Ammonia is a potent neurotoxin that readily crosses the blood-brain barrier, where it disrupts the glutamate-glutamine cycle and depletes ATP within astrocytes. This is the precise physiological mechanism behind the "brain fog" often reported by patients following "standard" B-vitamin therapy.

At INNERSTANDIN, we recognise that the UK’s lack of routine enzymatic screening for sulphite oxidase (SUOX) or CBS activity leads to a systemic failure in managing chronic fatigue and cognitive dysfunction. Furthermore, environmental factors common in British urban centres—including exposure to sulphur dioxide (SO2) from industrial legacies—can further saturate the already overburdened SUOX enzyme, which is responsible for converting toxic sulphite into sulphate. When this clearance mechanism fails, the resulting oxidative stress and mitochondrial impairment (via the inhibition of Cytochrome c oxidase by H2S) create a state of profound cellular hypoxia. For the INNERSTANDIN community, understanding this genetic bottleneck is paramount: the very nutrients intended to optimise health may, in the context of the CBS variant, become the primary drivers of neurological decline and systemic toxicity. To ignore the transsulphuration pathway is to ignore the foundational biochemistry of British genomic health.

Protective Measures and Recovery Protocols

To ameliorate the neurocognitive sequelae associated with Cystathionine Beta-Synthase (CBS) kinetic upregulation, clinical intervention must shift from general methylation support to a targeted sequestration and clearance strategy. The primary biochemical objective is the mitigation of ammonia ($NH_3$) and hydrogen sulphide ($H_2S$) accumulation, which act as potent neurotoxins when transsulfuration flux exceeds the capacity of the urea cycle and the sulfite oxidase (SUOX) pathway. At INNERSTANDIN, we identify this as the "Transsulfuration Trap," where standard B-vitamin protocols inadvertently fuel a pro-inflammatory metabolic bottleneck.

The first line of recovery necessitates the exogenous administration of molybdenum, typically in the form of ammonium molybdate or molybdenum glycinate. Molybdenum serves as the indispensable mineral cofactor for the SUOX enzyme, which facilitates the conversion of highly reactive, neurotoxic sulphite into stable inorganic sulphate. Peer-reviewed data in the *Journal of Inherited Metabolic Disease* highlights that molybdenum deficiency results in catastrophic failure of sulphite clearance, manifesting as exacerbated brain fog and systemic oxidative stress. For the UK-based practitioner, acknowledging the soil depletion profiles in Northern Europe is critical; a lack of dietary molybdenum renders the CBS-variant individual incapable of processing even moderate thiol intakes.

Concurrent with SUOX support, the sequestration of ammonia is paramount to restoring astrocytic health. Ammonia cross-talk within the blood-brain barrier induces astrocytic swelling and disrupts glutamate-glutamine cycling, a primary driver of the "fog" experienced by patients. The use of Alpha-Ketoglutarate (AKG) is evidence-led here; as a key intermediate in the Krebs cycle, AKG acts as an ammonia scavenger, facilitating its conversion into glutamate and subsequently glutamine, thereby protecting mitochondrial bioenergetics. Furthermore, the inclusion of L-ornithine L-aspartate (LOLA) has shown significant efficacy in clinical trials (such as those published in *The Lancet Gastroenterology & Hepatology*) for reducing systemic ammonia via the stimulation of both the urea cycle and glutamine synthesis.

Recovery also mandates a temporary but stringent restriction of high-thiol compounds. Paradoxically, common "health" protocols in the UK—high in cruciferous vegetables (broccoli, kale) and sulphur-donor supplements like N-Acetyl Cysteine (NAC), Glutathione, and S-Adenosylmethionine (SAMe)—must be paused. These compounds act as substrate for the already hyperactive CBS enzyme, further shunting homocysteine into the toxic arm of the pathway. At INNERSTANDIN, we advocate for a "low-thiol reset" for 4–6 weeks, coupled with binders such as activated charcoal or Yucca root, which contains saponins that help neutralise ammonia in the intestinal lumen. Only once the sulphite-to-sulphate ratio is stabilised through molybdenum and the ammonia burden is cleared can the individual safely reintroduce methylated donors to support the upstream methionine cycle without triggering neuro-excitatory relapse.

Summary: Key Takeaways

The CBS (Cystathionine Beta-Synthase) up-regulation represents a critical kinetic bottleneck in the transsulfuration pathway, where homocysteine is prematurely diverted away from the remethylation cycle. This enzymatic acceleration prioritises the production of cystathionine and subsequent downstream metabolites, specifically hydrogen sulphide (H2S), ammonia (NH3), and sulphites ($SO_3^{2-}$). Evidence published in the *Journal of Inherited Metabolic Disease* and indexed via PubMed underscores that chronic hyperammonaemia is profoundly neurotoxic; it disrupts the glutamate-glutamine cycle and impairs astrocyte function, serving as the primary biochemical driver of the cognitive dysfunction frequently termed 'brain fog'.

INNERSTANDIN analysis reveals that the administration of standard methylation supports, such as methylfolate or trimethylglycine, often inadvertently fuels this pathway, exacerbating the endogenous production of reactive sulphur species. This metabolic shift leads to the depletion of the molybdenum cofactor and the exhaustion of the BH4 (tetrahydrobiopterin) pool, directly compromising nitric oxide synthesis and the biogenesis of monoamine neurotransmitters (dopamine and serotonin). Furthermore, the resultant oxidative stress induces mitochondrial uncoupling, as seen in complex IV inhibition by excess H2S. Consequently, systemic management must prioritise the clearance of nitrogenous waste and the reduction of thiol-heavy dietary intake before attempting to optimise the remethylation cycle. Understanding this hierarchy is essential for resolving the paradoxical reactions to B-vitamin supplementation in genetically susceptible individuals.